Injectable versions of some widely-used cancer drugs including Johnson & Johnson’s blockbuster multiple myeloma treatment Darzalex are likely to be excluded from new U.S. government price negotiation.
https://www.pharmalive.com/wp-content/uploads/2021/08/Biden-to-urge-Congress-to-lower-prescription-drug-costs-Reuters-8-12-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-07-28 06:14:102023-07-28 10:22:32Drugmakers go under the skin, skirting early US Medicare price negotiations
